Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Future directions in T-cell lymphoma

Matko Kalac • 11 Jun 2022
EHA 2022
Lymphoma Rare Diseases T-Cell Lymphoma Antibodies Azacitidine CAR-T Romidepsin

Matko Kalac, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses future directions in T-cell lymphoma, highlighting a study investigating the use of romidepsin and azacitidine versus investigator’s choice, and further commenting on the potential use of CAR-T therapy and other novel agents. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Research: Johnson & Johnson

More from Matko Kalac

2:23
Romidepsin and azacitidine in patients with R/R T-cell lymphoma
Matko Kalac • 11 Jun 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals